Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
United StatesIPO:
25 October 2019Website:
http://www.progyny.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 15 Nov 2024 22:58:09 GMTDividend
Analysts recommendations
Institutional Ownership
PGNY Latest News
I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.
Why Progyny Stock Crashed Today
Progyny, Inc (NASDAQ:PGNY ) Q3 2024 Earnings Conference Call November 12, 2024 4:45 PM ET Company Participants James Hart - Investor Relations Peter Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Allen Lutz - Bank of America Sarah James - Cantor Fitzgerald Michael Cherny - Leering Partners Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Stephanie Davis - Barclays Scott Schoenhaus - KeyBanc Richard Close - Canaccord Genuity David Larsen - BTIG Operator Good day, and welcome to the Progyny, Inc. Third Quarter Earnings Conference Call. At this time all participants have been placed on listen-only mode.
Progyny (PGNY) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.16 per share a year ago.
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fertility benefits provider Progyny, Inc. (NASDAQ: PGNY) is under intense scrutiny following the unexpected announcement of a major client's departure.
SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ: PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended September 30, 2024 after the close of the market on Tuesday, November 12, 2024.
What type of business is Progyny?
Progyny, Inc. is an American company specializing in managing benefits in the field of reproductive health. Previously known as Auxogyn, Inc., the company changed its name to Progyny, Inc. in 2015. Progyny, Inc. was registered in 2008, with its headquarters located in New York, New York. The company offers the Smart Cycle treatment package, which includes all necessary diagnostic tests and access to the latest technologies (such as preimplantation genetic testing in the case of IVF treatment). Smart Cycle provides 17 different procedure packages that can be used independently or in combination, depending on the participant's needs. The company also offers Progyny Rx - a comprehensive pharmacy benefit solution that provides participants with access to medications needed during their treatment.
What sector is Progyny in?
Progyny is in the Healthcare sector
What industry is Progyny in?
Progyny is in the Health Information Services industry
What country is Progyny from?
Progyny is headquartered in United States
When did Progyny go public?
Progyny initial public offering (IPO) was on 25 October 2019
What is Progyny website?
https://www.progyny.com
Is Progyny in the S&P 500?
No, Progyny is not included in the S&P 500 index
Is Progyny in the NASDAQ 100?
No, Progyny is not included in the NASDAQ 100 index
Is Progyny in the Dow Jones?
No, Progyny is not included in the Dow Jones index
When was Progyny the previous earnings report?
No data
When does Progyny earnings report?
The next expected earnings date for Progyny is 27 February 2025